Application of frankincense diene alcohol acid in preparation of tumor radiosensitizer
By using styrax dienoic acid as a tumor radiosensitizer, inhibiting DNA damage repair and promoting apoptosis, the problem of tumor cell tolerance during radiotherapy was solved, and the therapeutic effect of radiotherapy was improved.
Patent Information
- Application Number
- CN202511304219.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-09-12
- Publication Date
- 2025-10-31
AI Technical Summary
Current radiotherapy techniques face challenges due to differences in radiosensitivity among patients caused by tumor heterogeneity. Some tumor cells have inherent or acquired radiation tolerance, leading to treatment failure and recurrence.
Boswellia dienol acid was used as a tumor radiosensitizer to improve radiosensitivity by inhibiting DNA damage repair in tumor cells and promoting radiation-induced apoptosis.
It significantly enhances the sensitivity of tumor cells to radiotherapy, improves the efficacy of radiotherapy, overcomes radiation tolerance, and expands the clinical application prospects of radiotherapy.
Smart Images
Figure CN120860207A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the field of radiotherapy drug technology, and in particular to the application of boswellia dienol in the preparation of tumor radiosensitizers. Background Technology
[0002] Radiotherapy, as one of the three major methods of cancer treatment, is used in over 50% of cancer patients worldwide, alongside surgery and chemotherapy. Its core mechanism involves inducing lethal DNA damage in tumor cells through high-energy radiation while minimizing damage to adjacent normal tissues. In recent years, with the continuous development of radiotherapy technology, including the application of various particle therapy methods such as intensity-modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT), and proton and heavy ion radiotherapy, the precision of dose distribution has been significantly improved, thereby increasing the local tumor control rate and reducing treatment-related toxicities, significantly improving treatment efficacy. However, the efficacy of radiotherapy still faces multiple limitations. Tumor heterogeneity leads to significant differences in radiosensitivity among patients, and some tumor cells possess inherent or acquired radiotolerance, which is a major cause of treatment failure and recurrence. Radiotolerance is usually closely related to mechanisms such as enhanced DNA damage repair capacity, the tumor hypoxic microenvironment, and resistance to apoptosis. Therefore, developing novel drugs that can enhance the radiosensitivity of tumor cells (radiosensitizing drugs) has become an important research direction in the field of radiation oncology. The aim is to overcome radiotolerance, improve treatment efficacy, and significantly expand the clinical application prospects of radiotherapy.
[0003] Masticadienolic acid is a tetracyclic triterpenoid compound with the molecular formula C2. 30 H 48 O3, with a molecular weight of 456.7, is a natural active ingredient in mastic gum. Masticadienolic acid exhibits biological activity against various cells and pathogens, possessing advantages such as novel structure, stable physicochemical properties, and diverse pharmacological effects. Currently, its analgesic, antibacterial, and anti-inflammatory effects are extensively studied. However, there are currently no reports on the use of fusarium oleoresin as an antiseptic for enhancing radiosensitivity. Summary of the Invention
[0004] The purpose of this invention is to provide the application of frankincense dienoic acid in the preparation of tumor radiosensitizers to enhance radiosensitivity.
[0005] To achieve the above-mentioned objectives, the present invention provides the following technical solution:
[0006] This invention provides the application of frankincense dienoic acid in the preparation of tumor radiosensitizing drugs.
[0007] Preferably, the structure of the frankincense dienoic acid is shown in formula (I).
[0008]
[0009] The present invention also provides a medicament for improving the radiosensitivity of tumors, the medicament containing the aforementioned boswellia dienol or a pharmaceutically acceptable salt, solvate or derivative thereof.
[0010] This invention provides the application of styrax dienoic acid in the preparation of tumor radiosensitizers. This invention offers a pharmaceutical strategy that can inhibit tumor cell DNA damage repair, promote radiation-induced apoptosis, and significantly improve radiosensitivity. It has the advantages of a well-known source, high safety, and wide applicability, and can provide a new solution for overcoming tumor radiotolerance and improving the efficacy of radiotherapy. Attached Figure Description
[0011] Figure 1 Effects of Boswellia dienyl acid combined with radiotherapy on tumor cell viability Detailed Implementation
[0012] This invention provides the application of frankincense dienoic acid in the preparation of tumor radiosensitizing drugs.
[0013] In this invention, the structure of the boswellia dienoic acid is shown in formula (I).
[0014]
[0015] In this invention, the masticadienolic acid was purchased from TargetMol Chemicals Inc. under the trade name Masticadienolic acid (trade number: TN4505).
[0016] The present invention also provides a medicament for improving the radiosensitivity of tumors, the medicament containing the aforementioned boswellia dienol or a pharmaceutically acceptable salt, solvate or derivative thereof.
[0017] The technical solutions provided by the present invention will be described in detail below with reference to the embodiments, but they should not be construed as limiting the scope of protection of the present invention.
[0018] Example 1: Effect of Boswellia dienyl acid combined with radiotherapy on tumor cell viability
[0019] Mouse colorectal cancer cell line MC38 and mouse melanoma cell line B16 were selected and cultured under standard conditions. Cells were cultured at a density of 3 × 10⁶ cells per well. 3 Individuals were inoculated into 96-well plates and cultured overnight before being divided into four treatment groups: control group (Ctrl), frankincense dienoyl acid treatment group (5 μM), radiation alone group (4 Gy), and frankincense dienoyl acid + radiation combined treatment group (5 μM + 4 Gy).
[0020] Drug treatment: Boswellia dienol (commercially available, purity ≥95%) was dissolved in DMSO at a working concentration of 5 μM; an equal volume of solvent was added to the control group.
[0021] Radiation treatment: Irradiation with a clinically common radiation source, at a dose of 4 Gy.
[0022] After 24 hours of treatment, cell viability was measured using a CCK-8 assay kit, and the results are as follows: Figure 1 As shown in the figure. The experimental results showed that both administration of styraxetine (5 μM) alone and radiotherapy alone (4 Gy) could lead to a decrease in cell viability; the combined treatment group (styraxetine + 4 Gy) showed the most significant decrease in cell viability, which was further reduced compared to the radiotherapy alone group, suggesting that styraxetine can enhance the radiation-induced cell killing effect.
[0023] As can be seen from the above embodiments, the present invention provides an application of styrax dialysate in the preparation of tumor radiosensitizers. The present invention has found that styrax dialysate can promote radiation-induced apoptosis, thereby significantly enhancing radiosensitivity.
[0024] The above description is only a preferred embodiment of the present invention. It should be noted that for those skilled in the art, several improvements and modifications can be made without departing from the principle of the present invention, and these improvements and modifications should also be considered within the scope of protection of the present invention.
Claims
1. Application of frankincense dienoic acid in the preparation of tumor radiosensitizing drugs.
2. The application according to claim 1, characterized in that, The structure of the frankincense dienoic acid is shown in formula (I).
3. A drug for improving the radiosensitivity of tumors, characterized in that, The drug contains the aforementioned boswellia dienol or a pharmaceutically acceptable salt, solvate, or derivative thereof.